1,100 reports of this reaction
1.6% of all FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE reports
#15 most reported adverse reaction
DYSPHONIA is the #15 most commonly reported adverse reaction for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, manufactured by GlaxoSmithKline LLC. There are 1,100 FDA adverse event reports linking FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE to DYSPHONIA. This represents approximately 1.6% of all 70,190 adverse event reports for this drug.
Patients taking FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE who experience dysphonia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPHONIA is a less commonly reported adverse event for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, but still significant enough to appear in the safety profile.
In addition to dysphonia, the following adverse reactions have been reported for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE:
The following drugs have also been linked to dysphonia in FDA adverse event reports:
DYSPHONIA has been reported as an adverse event in 1,100 FDA reports for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPHONIA accounts for approximately 1.6% of all adverse event reports for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, making it a notable side effect.
If you experience dysphonia while taking FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.